OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study
Year: 2021
Type: conference-abstract
Abstract: Rationale: Severe asthma is frequently associated with comorbidities.Nasal polyps (NP), in particular, indicate an eosinophilic phenotype and have been shown to predict an enhanced response to benralizumab in terms of asthma exacerbations and lung function.Increased serum immunoglobulin (Ig) E levels and atopy are also common in severe asthma, although they tend not to be associated with increased risk of exacerbations or predict response to biologics.Benralizumab has been shown to decrease long-term oral corticosteroid (OCS) use among patients with severe asthma, but whether the presence of comorbid NP, elevated serum IgE, or the presence of atopy impacts the degree of OCS reduction achieved with benralizumab is unknown.
Institutions: Queen's University Belfast, Royal Brompton & Harefield NHS Foundation Trust, University of Cambridge, Wellcome/MRC Institute of Metabolic Science, University of California, Los Angeles, Amsterdam University Medical Centers, University of Amsterdam, AstraZeneca (United Kingdom), University of Nottingham, Nottingham Biomedical Research Centre, Guy's Hospital, King's College London, Guy's and St Thomas' NHS Foundation Trust, Asthma UK, University of Aberdeen, Observational & Pragmatic Research Institute, University of Michigan, AstraZeneca (United States), AstraZeneca (Spain)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3160881399
